Biosenic On Its Way To Find The Necessary Funds To Perform Its Key Clinical Trial On Chronic Graft Versus Host Disease

    Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments

    Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, today announced financing of US$21 million in equity and debt financing. The round, led by Singapore-based SPRIM Global Investments (SGI), will help the company prepare for a Phase 3 clinical investigation of the company’s PRT120 oral therapy for peanut allergy.

    Read More

Latest News